Fera Pharmaceuticals has announced the launch of Neptazane (Methazolamide), an oral treatment option for physicians and patients who require effective reduction of intraocular pressure (IOP).
According to the company, the drug is intended for use in the treatment of ocular conditions where lowering IOP is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma.
David Cobb, vice-president of ophthalmics for Fera, pointed out that high IOP can lead to glaucoma if left untreated.
"Neptazane represents an alternative to eye drops when IOP is not effectively controlled or patient compliance becomes an issue. And Neptazane is a brand name the eye care community knows," he said.
Recent research conducted by Glaucoma Research Foundation estimated that only half of those with the condition are aware of it, with two per cent of the population aged 40-50 and eight per cent over 70 having elevated IOP.
by Emily Tait